European decentralised procedure for belkyra® (deoxycholic acid) for patients with submental fullness

News Hour:

Allergan plc (NYSE: AGN), a leading global pharmaceutical company,  announced that it has received a Positive Opinion from the Swedish Medical Products Agency (MPA) for BELKYRA® (deoxycholic acid). BELKYRA® will be the first prescription medicine to be licensed in Europe for the treatment of moderate to severe convexity or fullness associated with submental fat (often called double chin) in adults when the presence of submental fat has a psychological impact for the patient. BELKYRA® is being evaluated through the Decentralised Procedure, with the Swedish MPA acting as the Reference Member State for 20 other countries in the European Union, as well as Iceland and Norway.

  Learn about the COVID-19 pandemic from News Hour  

“We are delighted to receive the Positive Opinion from the Swedish Medical Products Agency (MPA) for BELKYRA®, which provides men and women who are bothered by submental fullness with a new minimally invasive treatment option,” said David Nicholson, Chief R&D Officer at Allergan. “Because of the extensive evidence behind the product, we see BELKYRA® as a breakthrough treatment that will complement other aesthetic treatments. We look forward to our continued work with the 20 EU member states, Norway and Iceland to secure marketing authorizations to make this important new treatment option available to customers and patients.”

Submental fullness (or double chin) is a concern for many people. In fact, according to data from the American Society for Dermatologic Surgery (ASDS) in 2015, fat under the chin/neck topped the list of most troublesome conditions for patients, with 67% reporting being concerned or bothered about the condition.There is a common misperception that fullness under the chin only appears in those who are overweight, when in reality it can occur in any body type and may be related to aging, genetics or weight gain.

“In my practice, I see many patients – both men and women – whose self-esteem has been negatively impacted by fullness under their chin; often the way they feel on the inside is contrary to what they see when they look in the mirror,” said Leading Cosmetic Physician David Eccleston. “I would welcome the addition of a minimally invasive, clinically proven, authorized prescription medicine that meets Good Manufacturing Practice Standards to my practice, and it would give me confidence to be able to offer an effective and proven solution for double chin (submental fullness) to my patients.”

“Once approved, BELKYRA® will provide a complementary fit to our broader medical aesthetics portfolio. We are looking forward to bringing the product to market and training physicians on how to best use this new treatment,” said Paul Navarre, President, Allergan International.

BELKYRA® has been the focus of a global clinical development programme involving over 20 clinical studies with more than 2,600 patients worldwide. Four phase III clinical studies have assessed the efficacy and safety of BELKYRA® in adults with moderate to severe fullness under the chin; two in the US and two in Europe. In the clinical studies, clinicians assessed that 63.8% of people treated with BELKYRA® in the European studies and 78.5% of patients in the North America studies achieved a 1-grade improvement in the appearance of the area beneath their chin at 12 weeks after their last treatment. Importantly, 44.6% of people treated with BELKYRA® in the European studies and 48.6% in the North American studies reported improvement in the psychological impact due to their submental fullness (compared with 18% and 17.3% of people treated with placebo, respectively) during the same time period.BELKYRA® was generally well tolerated. Most side effects were mild or moderate in severity, primarily associated with the treatment area and resolved without intervention.

As a next step, Allergan will work to secure the national Marketing Authorisations in the Concerned Member States. Once the national licenses have been granted,Allergan will begin to train healthcare professional customers on the safe and effective use of this new treatment. Allergan is already working with other health regulatory agencies around the world to bring this valuable treatment option to people with submental fullness. BELKYRA® is already licensed in Canada, as well as in the U.S. as KYBELLA®.

Follow News Hour
Rafiuzzaman Sifat

Md. Rafiuzzaman Sifat, a CSE graduate turned into journalist, works at News Hour as a staff reporter. He has many years of experience in featured writing in different Bangladeshi newspapers. He is an active blogger, story writer and social network activist. He published a book named 'Se Amar Gopon' inEkushe boi mela Dhaka 2016. Sifat got a BSc. from Ahsanullah University of Science & Technology, Bangladesh. He also works as an Engineer at Bangla Trac Communications Ltd. As an avid traveler and a gourmet food aficionado, he is active in publishing restaurant reviews and cutting-edge articles about culinary culture.
No Comments
Scroll Up
%d bloggers like this: